This article is more than 5 years old. Information may no longer be current.

Macugen reimbursement terms announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — The Centers for Medicare & Medicaid Services announced a reimbursement level for a recently approved drug for age-related macular degeneration.

Effective Jan. 1, Macugen (pegaptanib sodium, Eyetech/Pfizer), will be reimbursed under Medicare Part B at 106% of the average sales price, or $1,054.70 per injection, according to a press release from the drug’s marketers.

Macugen was approved by the Food and Drug Administration in December for use in the treatment of neovascular AMD. Eyetech and co-marketer Pfizer launched Macugen in the United States last month.